Moteur de recherche d’entreprises européennes
Financement de l’UE (6 000 000 €) : Tolérance au rhumum pour la guérison Hor 01/09/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Tolérance au rhumum pour la guérison
In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tolerising treatments of subjects not only in early stages of joint inflammation (undifferentiated arthritis and early RA) but also in even earlier defined stages i.e. before onset of joint inflammation, when patients have arthralgia and/or bone loss, or sub-clinical stages of joint inflammation. Today, no drugs are approved for these early phases of RA development, where symptoms such as pain and fatigue cause major loss of life quality and where successful interference would prevent onset of disease. Thus, an important part of our work will be to achieve a better understanding of this as yet unexplored phase of disease. In the proposed project we will develop and validate new methods to identify individuals at high risk for RA, tools to monitor disease progress and expand and further develop cohorts suitable for these purposes. Furthermore we will validate and standardise methods to monitor immune tolerance to be used in clinical trials for tolerising therapies for RA. The aim is thus to interfere with the specific immune reactions that contribute to RA symptoms in such a way that a specific and long-lasting therapeutic effect (ultimately a cure) is accomplished for a major proportion of RA patients and prevention of diseases is accomplished in individuals at high risk for RA. Investigator-initiated as well as company-sponsored clinical trials in well stratified patient groups will be performed in collaboration with SMEs and/or contributing pharma companies and their immune effects studied using the same panel of biomarkers allowing for standardisation across protocols. Our ambition is also to disseminate our experiences from RA to other rheumatic and other immune-mediated diseases.
| Academisch Ziekenhuis Leiden | 573 175 € |
| Anocca AB | 138 484 € |
| Apitope International N.V. | 169 337 € |
| Bristol-Myers Squibb Company Corp | 0,00 € |
| Deutsches Rheuma Forschungszentrumberlin | 453 450 € |
| Fondazione Per L'Istituto Di Ricerca IN Biomedicina | 182 700 € |
| Glaxosmithkline Research & Development Ltd. | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| Karolinska Institutet | 1 293 376 € |
| King's College London | 475 165 € |
| Medizinische Universitaet Wien | 446 725 € |
| Pfizer Ltd. | 0,00 € |
| Sanofi-Aventis Deutschland GmbH | 0,00 € |
| Semmelweis Egyetem | 173 700 € |
| The University of Birmingham | 448 075 € |
| THE University OF Queensland | 298 000 € |
| UCB Biopharma | 0,00 € |
| Universitatsklinikum Erlangen | 449 730 € |
| University of Glasgow | 448 725 € |
| University of Newcastle Upon Tyne | 449 358 € |
https://cordis.europa.eu/project/id/777357
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.